Screener
Kestra Medical Technologies KMTS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kestra Medical Technologies in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Kestra Medical Technologies’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 5:16 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001193125-26-303397
| Line item | Year Ended April 30, 2026 | Year Ended April 30, 2025 |
|---|---|---|
| Payment of equity issuance costs | (2,466) | (3,224) |
| Deemed dividend for payments to third party on behalf of shareholder | (323) | (1,654) |
| Proceeds from stock option exercises | 593 | - |
| Net cash provided by financing activities | 147,095 | 330,262 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (137,885) | 229,346 |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 237,929 | 8,583 |
| End of period | $100,044 | $237,929 |
Item 16. Form 10-K Summary.
FAQ
- What is Kestra Medical Technologies's financing cash flow?
- Kestra Medical Technologies (KMTS) reported financing cash flow of $0 in Q1 2026.
- How has Kestra Medical Technologies's financing cash flow changed year-over-year?
- Kestra Medical Technologies's financing cash flow decreased by 100.0% year-over-year, from $214.7M to $0.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Kestra Medical Technologies's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude